Buzz of BIO at BIF 2015

  • Recommend
  • Tweet
  • Print
  • Email

buzz header winners.jpg

Congratulations to Our Winners!

The Buzz of BIO at the BIO Investor Forum competition featured 19 nominees pulling in over 3,000 votes. Winners receive one complimentary registration to the BIO Investor Forum, a complimentary Company Presentation and promotion to industry leaders including a spotlight in BioCentury Extra. 

The Buzz of BIO contest drew a record breaking 3,000 collective votes. This year's winners will join more than 120 companies presenting at the BIO Investor Forum. New presenters are continuously being added. For updates on the list of presenting companies, please visit here. If you are interested in becoming a presenter, please submit an application here. The typical audience for company presentations features public, institutional and private equity investors, research analysts, investment bankers and industry executives.

Don't forget to register for the BIO Investor Forum!

whole biome.jpg

Whole Biome is a laboratory/computational platform company with technology capable of generating and analyzing the huge volumes of genomic and phenotypic data necessary to elucidate the functional components of the human microbiome. By targeting novel symbiotic functionality inherent in the human-microbial interface, Whole Biome has identified multiple therapeutic targets for: metabolic disease, atopic dermatitis, and pre-term labor. Whole Biome’s flagship microbiome therapeutic for type II diabetes has shown promising preclinical data and is anticipated to be tested in humans in 2016.

cold genesys.jpg

Cold Genesys is a clinical-stage company focusing on the development of oncolytic viruses and immunotherapies for cancer. In 2010, Cold Genesys acquired the rights to develop CG0070 from BioSante Pharmaceuticals. A phase I/IIa dose escalating clinical trial has already been completed in 35 patients with nonmuscle invasive bladder cancer (NMIBC). With the promising results from the phase I study, Cold Genesys is currently investigating the company’s first oncolytic virus product, CG0070, in a phase II pivotal, single-arm clinical study with the FDA for NMIBC patients who have failed BCG therapy and refused cystectomy. In addition, Cold Genesys is exploring the use of CG0070 in combination with immune checkpoint modulators (ICMs) in various solid tumors.